Volume 7 Supplement 1
Clinical and immulogical outcomes among adult patients receiving Antiretroviral Therapy (ART) at an HIV/AIDS program in Uganda
© Muhumuza et al; licensee BioMed Central Ltd. 2010
Published: 11 May 2010
To evaluate clinical and immunological outcomes and the associated factors among adult patients receiving ART at MJAP, Uganda.
A retrospective cohort analysis of patient data on ART between August 2005 and June 2009 at Mulago Hospital AIDS (ISS) clinic.
Changes in Body Mass Index (BMI) and CD4 cell count, incidence of Opportunistic Infections (OIs) and mortality were compared with the patients' socio-demographics, WHO stage and CD4 count at initiation of ART, ART regimen and adherence levels. Odds ratios, 95% confidence intervals, chi square tests, logistic regression and Cox proportional hazard model were used for analysis.
Of the 4,824 patients on ART, 65% (3,120) were female, median age; 33 years (IQR: 28-40). Total follow up time was 5824.9 Person Years (PY). Median CD4+ count and BMI at ART initiation was 138 cells/mm3 (IQR: 60-200) and 21.2 kg/m2 (IQR 19.2-23.7) respectively. 10.6% developed OIs, 239 (5%) patients died. Incidence of death was 4.12/100 PY (95% CI 3.63-4.68). Gain in CD4 count and BMI was observed in 68% and 63% of the patients respectively. Median increase in CD4 count was 174 cells/mm3 (IQR 96-278) and mean increase in BMI was 1.5 kg/m2 (S.D 2.82).
Increase in CD4 count and BMI was associated with increased income, adherence ≥ 95%, WHO stages III & IV and CD4 count < 100 (P < 0.05). The risk of developing an OI was associated with CD4 count < 100, WHO stages III & IV (P < 0.001) and decreasing levels of education (c2 for trend = 7.7 (df) = 1, P = 0.005). Mortality was higher in patients in WHO stage III & IV (H.R 2.57, P < 0.001) and lower in patients with CD4 count ≥100, (H.R 0.32, P < 0.001) and adherence ≥ 95% (HR 0.55, P < 0.001).
Early initiation of ART, good adherence, improved income and education status are associated with increased survival and positive clinical and immunological outcomes among patients on ART.
This article is published under license to BioMed Central Ltd.